RESULTS	Viral breakthrough and genotypic mutations were detected in 8 ( 27.6 % ) and 4 ( 13.3 % ) patients in the ADV monotherapy and ADV+LAM therapy groups , respectively ; whereas no case of viral breakthrough and genotypic resistance was detected in the ADV+ETV combination therapy group after 24 months ( p < 0.05 ) .\